E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute peripheral arterial occlusions. Acute peripheral arterial occlusive disease can be caused by a blood clot blocking an artery in an arm or leg. This is an emergency situation that can result in amputation or be life threatening if not treated promptly. |
|
E.1.1.1 | Medical condition in easily understood language |
A disease in which a blood clot blocks an artery of the leg. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to test whether thrombolysis with additional contrast-enhanced ultrasound is applicable in patients with peripheral arterial occlusions. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to investigate the safety of microbubble and ultrasound enhanced intra-arterial thrombolysis and if it is logistically feasible in our university hospital. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Men and women older than 18 years and younger than 85 years old • Patients with a maximum of 7 weeks complaints due to lower limb ischemia due to thrombosed/occluded iliofemoral, femoropopliteal or femorocrural native arteries or femoropopliteal or femorocrural venous or prosthetic bypass grafts • Anatomic suitability duplex ultrasound in case of iliac occlusion • Patients fit for thrombolysis i.e. with acute lower limb ischemia class I and IIa according to the Rutherford classification (see attachment II) • Patients understand the nature of the procedure and provide written informed consent before enrolment in the study |
|
E.4 | Principal exclusion criteria |
• Patients with clinical complaints of acute lower limb ischemia due to thrombosis of the iliofemoral, femoropopliteal or femorocrural native arteries, or femoropopliteal or femorocrural venous or prosthetic bypass grafts more than 7 weeks • Patients with iliac occlusions anatomically not suitable for duplex ultrasound • Patients with thrombosed popliteal aneurysms • Patients with contra-indications for the administration of antiplatelet therapy, anticoagulants or thrombolytics • Recent (less than 6 weeks) ischemic stroke, cerebral bleeding or myocardial infarction • Patients with recent (less than 6 weeks) surgery • Severe hypertension (diastolic blood pressure greater than 110 mm Hg, systolic blood pressure higher than 200 mm Hg) • Current malignancy or severe comorbid condition with a life expectancy of less than 6 months • Patients with uncorrected bleeding disorders (gastrointestinal ulcer, menorrhagia, liver failure) • Women with child-bearing potential not taking adequate contraceptives or currently breastfeeding • Pregnancy • Patients who are currently participating in another investigational drug or device study • Patients younger than 18 years or older than 85 years • Patients with contra-indications for Luminity microbubbles i.e. • Hypersensitivity to sulphur hexafluoride or to any of the components of Luminity, • Recent acute coronary syndrome or clinically unstable ischemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within last 7 days, significant worsening of cardiac symptoms within last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (for example, recent deterioration of ECG, laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders • Patients known to have right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure >90 mmHg), uncontrolled systemic hypertension, and in patients with adult respiratory distress syndrome.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Main endpoints will be the duration of thrombolysis needed for uninterrupted flow in the thrombosed native artery or bypass graft with outflow through at least 1 crural artery and microcirculation of the lower limb as measured by Laser Doppler Flowmetry on the skin of the lower limb. Furthermore, Severe Adverse Events (haemorrhagic complications, allergic reactions, in hospital mortality directly related to the treatment) and amputation-free rate at 6 months. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Duration of thrombolysis: at cessation of therapy: ultrasound duplex every 6 hours, SAE's during hospital stay, amputation-free rate at 6 months. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints will be the angiographic success rate, microcirculatory flow, distal thromboembolic complications, other complications, 30 day mortality rate, conversion to open surgery, duration of hospital admission, serum fibrinogen concentrations, pain scores and quality of life. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Angiographic success rate at last angiography before treatment cessation, complications during hospital stay, mortality rate at 30 days, conversion to open surgery during thrombolytic therapy, serum fibrinogen concentrations during thrombolytic therapy, ultrasound duplex and microcirculatory flow every 6 hours during treatment, pain scores before treatment initiation, every three hours during thrombolytic treatment and follow-up at 3 months, 6 months and 1 year, quality of life at baseline (before treatment initiation), and during follow-up at 3 months, 6 months and 1 year. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |